In the last decade or so, our knowledge of the roles of the steroids referred to as 'sex hormones' namely testosterone and estradiol, has undergone a quiet revolution. In the first place, models of androgen and estrogen insufficiency, whether they be natural or engineered, have revealed new and unexpected roles for sex steroids, some of which have nothing to do with reproduction.
Introduction
In the last decade or so, our knowledge of the roles of the steroids referred to as 'sex hormones' namely testosterone and estradiol, has undergone a quiet revolution. In the first place, models of androgen and estrogen insufficiency, whether they be natural or engineered, have revealed new and unexpected roles for sex steroids, some of which have nothing to do with reproduction.
Furthermore both categories of steroid have roles in both sexes which blunts the definition of the terms 'androgen' and 'estrogen'. Secondly, the gradual acceptance of the role of local steroid hormone action, particularly as it applies in postmenopausal women and in men, provides new insights into the significance of paracrine and intracrine actions, and requires a re-evaluation of the importance of circulating steroid hormone levels. This article will attempt to review both of these developments, particularly in the context of the work of this laboratory on the aromatase knock-out (ArKO) mouse and the role of local aromatase expression within the breast and breast cancer.
The concept of local estrogen biosynthesis
Models of estrogen insufficiency have revealed new and unexpected roles for estrogens in both males and females. These models include natural mutations in the aromatase gene, as well as mouse knockouts of aromatase and the estrogen receptors (1) (2) (3) (4) (5) (6) . In addition there is one man described with a natural mutation in the ERα (7) . Some of the roles of estrogens apply equally to males and females and do not relate to reproduction, for example the bone, vascular
and Metabolic Syndrome phenotypes.
In postmenopausal women and in men, estradiol does not appear to function as a circulating hormone, instead it is synthesised in a number of extragonadal sites such as breast, brain and bone where its actions are mainly at the local level as a paracrine or intracrine factor. Thus in postmenopausal women and in men, circulating estrogens are not the drivers of estrogen action, rather they reflect the metabolism of estrogens formed in these extragonadal sites, they are reactive rather than proactive (8) . Importantly, estrogen biosynthesis in these sites depends on a circulating source of androgenic precursors such as testosterone. Table 1 shows the plasma steroid levels in postmenopausal women and in men. As can be seen, the levels of estrone and estradiol in the plasma of postmenopausal women are extremely low, lower in fact than those in the circulation of men; and moreover the levels of circulating testosterone are an order of magnitude greater than those of estrogens in postmenopausal women.
This in itself would suggest that circulating testosterone is better placed to serve as a precursor of estradiol in target tissues than is circulating estradiol.
On the other hand, the levels of testosterone in the blood of men are an order of magnitude higher than those of women. Significantly, levels of DHEA and DHEAS in the blood of both men and women are orders of magnitude higher than those of the circulating active steroids. In postmenopausal women, the ovaries secrete 25-35% of the circulating testosterone. The remainder is formed peripherally from androstenedione and DHEA produced in the ovaries, and from androstenedione, DHEA and DHEAS secreted by the adrenals.
However, the secretion of these steroids and their plasma concentrations decrease markedly with advancing age (9) . Figure 1 shows the metabolism of testosterone and estradiol in a typical target cell (8) . Testosterone in this cell can be derived from the uptake of testosterone or else of androstenedione, DHEA or DHEAS, all of which can be converted in the target cell to testosterone. Testosterone in turn can act directly on the androgen receptor or else be converted to DHT which then acts on the androgen receptor. Alternatively, testosterone can be converted to estradiol which in turn acts on the estrogen receptor. Testosterone and estradiol can then leave the cell as such or else be converted to reduced and conjugated metabolites which circulate in the blood at concentrations higher than those of the active steroids (8) . Based on these considerations it is difficult to see how one can readily equate plasma levels of testosterone and estradiol to the concentrations which are present in target cells. These considerations lead to the following conclusions regarding the significance of peripheral steroid metabolism:
1.
Women and men make close to equal amounts of testosterone and estradiol (say, 50% rather than 10% in the case of women relative to men) and both have major physiological roles in both sexes.
2.
However, in premenopausal women, most of the testosterone is formed, acts, and is metabolized in specific target tissues. It is a paracrine and intracrine factor whereas in men it circulates as a hormone and acts globally.
3.
On the other hand in men most of the estradiol is formed, acts and is metabolized in specific target tissues whereas in women it circulates as a hormone and acts globally.
4.
Finally, in postmenopausal women on the other hand, neither testosterone nor estradiol function to any extent as a circulating hormone. Both are mainly formed locally in target tissues and act and are metabolized therein.
The power of local estrogen biosynthesis is illustrated in the case of postmenopausal breast cancer (10) . It has been determined that the concentration of estradiol present in breast tumors of postmenopausal women is at least 20-fold greater than that present in the plasma. With aromatase inhibitor therapy there is a precipitous drop in the intratumoral concentrations of estradiol and estrone together with a corresponding loss of intratumoral aromatase activity, consistent with this activity within the tumor and the surrounding breast adipose tissue being responsible for these high tissue concentrations (11) .
In bone, aromatase is expressed primarily in osteoblasts and chondrocytes (12) , and aromatase activity in cultured osteoblasts is comparable to that present in adipose stromal cells (13) . Thus it appears that in bone also, local aromatase expression is a major source of estrogen responsible for the maintenance of mineralization, although this is extremely difficult to prove due to sampling problems. Hence for both breast tumors and for bone, it is likely that circulating estrogen levels are minimally responsible for the relatively high endogenous tissue estrogen levels; rather the circulating levels reflect the sum of local formation in its various sites. This is a fundamental concept for the interpretation of relationships between circulating estrogen levels in postmenopausal women and estrogen insufficiency or excess in specific tissues.
The second important point is that estrogen production in these extragonadal sites is dependent on an external source of C 19 androgenic precursors, since these extragonadal tissues are incapable of converting cholesterol to the C 19 steroids (14,9) . As a consequence, circulating levels of testosterone and androstenedione as well as DHEA and DHEAS become extremely important in terms of providing adequate substrate for estrogen biosynthesis in these sites, and therefore differences in the levels of circulating androgens are likely to be important determinants for the maintenance of local estrogen levels in extragonadal sites.
In this context it is appropriate to consider why osteoporosis is more common in women than in men and affects women at a younger age in terms of fracture incidence. We have suggested that uninterrupted sufficiency of circulating testosterone in men throughout life supports the local production of estradiol by aromatization of testosterone in estrogen-dependent tissues, and thus affords ongoing protection against the so-called estrogen deficiency diseases.
This appears to be important in terms of protecting the bones of men against mineral loss and may also contribute to the maintenance of cognitive function and prevention of Alzheimer's disease (15) . The human CYP19 gene was cloned some years ago (16) (17) (18) , when it was shown that the coding region spans 9 exons beginning with exon II. Upstream of exon II are a number of alternative first exons which are spliced into the 5'-untranslated region of the transcript in a tissue-specific fashion (Fig 2) . For example placental transcripts contain at their 5'-end a distal exon, I.1. This is because placental expression is driven by a powerful distal promoter upstream of exon I.1 (19) . Examination of the Human Genome Project data reveals that exon I.1 is 89kb upstream of exon II (20) . On the other hand, transcripts in ovary and testes contain at their 5'-end sequence which is immediately upstream of the translational start site. This is because expression of the gene in the gonads utilizes a proximal promoter, promoter II. By contrast, transcripts in cells of mesenchymal origin such as adipose stromal cells and osteoblasts, contain yet another distal exon (I.4) located 20kb downstream of exon I.1, (21) . Adipose tissue transcripts also contain promoter II-specific exonic sequence, but these are undetectable in bone (13) .
Aromatase and its gene
Splicing of these untranslated exons to form the mature transcript occurs at a common 3'-splice junction that is upstream of the translational start site. This 
The aromatase (ArKO) mouse
In order to investigate the phenotypes resulting from lack of estrogen, some years ago we and others generated the aromatase knockout (ArKO) mouse (5, 6, 23, 24) . This was done by replacing most of exon 9 with the neomycin resistance cassette. Since exon 9 contains many of the amino acids involved in substrate binding, and many of the natural point mutations which result in a complete loss of aromatase activity are located in exon 9, deletion of this exon results in a complete abrogation of aromatase activity. The main features of the phenotype of the ArKO mouse can be summarised as follows: Infertility and lack of sexual behaviour in both males and females, progressive defects in folliculogenesis and spermatogenesis; elevated gonadotropins and T levels; loss of bone mass in both sexes; and a Metabolic Syndrome with insulin resistance, truncal obesity and hepatic steatosis. Many, but not all aspects of this phenotype are also present in the ERαKO and ERα/βKO mice (reviewed in 25). The requirements of estrogen for male sexual behaviour and for maintenance of male bone mineralization were quite unexpected at the time, but space does not permit discussion of these aspects, which can be found in refs 26, 27 and 28. Instead we will focus here on the role of estrogen in energy homeostasis.
The ArKO mouse and the Metabolic Syndrome
From the age of 12-14 weeks onwards, ArKO mice develop a progressive phenotype of truncal obesity with increased adiposity in the gonadal and visceral fat pads (6) . MRI data shows that ArKO females have 3-4 times as much adipose as wild-types, whereas males have twice as much, so this phenotype of increased adiposity is more marked in the females than in the males. As might be expected then, serum leptin levels are also elevated as shown in Table 2 so that by 1 year of age, ArKO females have 3 times as much circulating leptin as do the wild-types whereas males have twice as much, consistent with the degree of adiposity in the males and females.
Measurement of serum insulin reveals that the ArKO mice develop hyperinsulinemia so that by 1 year of age male ArKO mice have 3 times the level of circulating insulin as do the wild-types (Table 3 ) (6) . However serum glucose levels remain steady indicating that at 1 year of age the animals have not progressed to full Type 2 diabetes. In spite of the marked increase in adiposity, there was not such a dramatic increase in body weight leading us to suspect there could be a decrease in lean body mass. This was found to be the case, suggesting a decrease in skeletal muscle mass (8) . To investigate this, energy balance studies were conducted. These indicated that there was no change in resting energy expenditure or fat oxidation but there was about a 50% reduction in the glucose oxidation rate. There was also a decrease of about 50% in daily ambulatory movements. Since most glucose oxidation is accounted for by skeletal muscle activity, these results are consistent with the insulin resistance being primarily a function of impaired skeletal muscle activity (6) .
We then went on to conduct estrogen replacement studies by the use of silicone implants containing estradiol which give plasma levels of estradiol of around 50pg/ml, in other words approximately the levels seen at the peak of the estrous cycle, thus within the physiological range (29) . To our surprise, after 21 days there was a dramatic decrease in the visceral fat masses to levels well below those seen with the wild-type placebo controls. This was largely a function of changes in the volume of the adipocytes since there was little change in adipocyte number. We also examined the levels of enzymes and factors involved in de novo fatty acid synthesis such as PPARγ, PGC1-α, fatty acid synthase and acetyl CoA carboxylase, but there were no significant changes in expression of these factors. Instead the increase in adiposity appeared to be primarily due to an increase in the expression of lipoprotein lipase, the enzyme responsible for hydrolysing triglycerides in chylomicra micra and VLDL such that the resulting free fatty acids and sn-2 monoglycerides are taken up by the adipose cells and resynthesised into triglycerides. Expression of this enzyme was elevated 3-4 fold in the ArKO mice (29) and profoundly inhibited by estradiol replacement.
While conducting these experiments we noticed that the livers of the male ArKO mice were paler in colour than those of the wild-types or of the females.
Microscopic examination revealed that the livers of the male ArKO mice were engorged in lipid whereas those of the females were not (30) (Fig.3) . Analysis of the lipid content revealed that this was primarily due to a 4-5 fold increase in the triglyceride content of the male ArKO livers. Treatment with estradiol for 6 weeks effectively blocked this increase in hepatic lipid accumulation.
Thus the phenotype of the ArKO mice is characterised by a markedly sexually dimorphic lipid partitioning with the increase in lipid in the case of the females occurring primarily in the visceral adipose depots, whereas in the males there is a shift in lipid deposition such that an increased proportion is deposited in the liver, resulting in marked hepatic steatosis. We also examined the expression of enzymes involved in fatty acid synthesis in the livers of these mice and found that in the males there was a 3-4 fold increase in the expression of fatty acid synthase and of acetyl CoA carboxylase-α. There was a similar increase in the levels of ADRP, a fatty acid transporter. Again these increases were normalised by estradiol replacement (30) .
In order to understand the basis for this sexually dimorphic phenotype, we are currently examining the hypothalami of the brains of these animals. Previous studies from Gustafsson's laboratory (31) and also the labs of Korach and Negishi (32) Currently about a dozen or so individuals have been characterised with natural aromatase mutations, of whom 5 are men (34) (35) (36) (37) (38) . The women so far described have been diagnosed at the time of puberty and placed on estrogen replacement, so it has not been possible to study their lipid and carbohydrate profiles. Consequently these studies have been confined to men with aromatase mutations. The most recent study is of an Argentinian male whose phenotype was characterised by Dr Laura Maffei and her colleagues in Buenos
Aires and Dr Cesare Carani and his colleagues in Modena, Italy (38) . His metabolic parameters are presented in Table 4 . As can be seen, his glucose and insulin levels are markedly elevated and these levels are decreased after estradiol replacement. He also has acanthosis nigricans. Based on this he was diagnosed as having Type 2 diabetes at the age of 29 years. Estradiol replacement also caused a decrease in total circulating and LDL cholesterol and an increase in HDL cholesterol. His liver function parameters were also profoundly elevated as indicated in Table 4 and once again these were markedly reduced upon estrogen replacement. A liver biopsy revealed substantial macro-and microsteatosis as well as portal vein fibrosis and steatosis. He also had carotid plaques which are unusual in a man of his relative youth and once again these disappeared after estrogen treatment. Thus this man with a natural mutation in aromatase has a Metabolic Syndrome phenotype which is similar in many ways to that of the male ArKO mice.
Summary of the metabolic effects of estrogens
Based on these results, we can conclude that estrogen has an important role to play in energy homeostasis in both mice and men. Lack of estrogen results in the development of a Metabolic Syndrome. This results in a sexually dimorphic partitioning of lipids such that in males there is profound hepatic steatosis which is not seen in females. Estrogen administration results in a prompt reversal of these symptoms. We conclude that estrogen is another hormone synthesized in brain, muscle and adipose which acts to regulate energy homeostasis along with leptin, adiponectin, resistin and cortisol.
Because aromatase inhibitors are coming into widespread use as breast cancer therapy and probably also as chemo-prevention, potential metabolic disturbances with long-term use of these compounds should be monitored.
Local aromatase expression in the breast and breast cancer.
As indicated previously, aromatase expression in the breast is implicated as the main source of estrogen driving breast cancer development. Studies to examine aromatase activity and expression in breast cancer quadrants have indicated that this activity is highest in quadrants of the breast containing a tumor (39, 40) . Indeed there is a gradient of aromatase expression extending from a tumor, such that expression in the tumor-containing quadrant is equal to that in the tumor itself, but double that in a quadrant of the same breast which does not contain a tumor, which in turn is double again the expression present in a cancer-free breast (41) . These results suggest that the tumor is elaborating a factor or factors which stimulate aromatase expression within the tumor and in the surrounding adipose tissue.
In order to understand which factor or factors might be responsible, we and others have examined not only total aromatase transcript expression but also expression of promoter-dependent transcripts (41-43) (Fig.4) . In adipose tissue of healthy breast as indicated previously, aromatase expression is low and is driven primarily by a distal promoter I.4 which is regulated by Class 1 cytokines and TNFα produced locally in the tissue and acting in a paracrine and autocrine fashion. On the other hand, in the presence of a tumor, the increase in aromatase expression is due primarily to an increase in expression driven off the proximal gonadal promoter, promoter II. This promoter is regulated by factors which stimulate adenylate cyclase. We reasoned that a likely candidate produced by tumors would be PGE 2 , and indeed it turned out that PGE 2 is a most powerful stimulator of aromatase expression in human breast adipose stromal cells (44, 45) (Fig.5) . Moreover, recent work has indicated that estrogen has a role itself in up-regulating PGE2 synthesis and aromatase in estrogen-receptor-positive breast cancer cells (46) A number of case-controlled or observational trials have indicated that these compounds are indeed of benefit in terms of breast cancer chemoprevention (47) (48) (49) . Indeed in one such trial, regular use of ibuprofen resulted in as much as a 50% decrease in the incidence of breast cancer over the study period (47) . Several randomized double-blind placebo-controlled trials are currently underway to examine the utility of specific COX2 inhibitors as a breast cancer therapy (49) . In the meantime, phase 3 aromatase inhibitors are proving superior to Tamoxifen as first-line and adjuvant therapy and neoadjuvant therapy for breast cancer. Moreover they show benefit as second line therapy and a dramatic decrease in the incidence of contralateral breast cancer (reviewed in 50) compared to Tamoxifen. They also showed decreased ischemic cerebral vascular and thromboembolic events as well as decreased endometrial cancer.
However there are down sides to the use of these compounds. This stems from the fact that since these are highly specific and high affinity inhibitors of the catalytic activity of aromatase, they inhibit aromatase activity in every site of expression, not only in breast but also in bone, brain and other sites. Not surprisingly therefore, their use is associated with an increase in bone loss and fracture risk. Interestingly there is also an increase in arthralgia or inflammatory joint pain (50) , and based on the studies discussed earlier in this chapter, it might be anticipated that there is a potential for a poorer lipid profile as well as perhaps development of a Metabolic Syndrome with long term use although as yet there is no evidence for this.
For these reasons therefore, there will clearly be a benefit if one could specifically inhibit aromatase in the breast but leave other sites of expression such as bone protected. The only way to do this is to specifically inhibit aromatase expression within the breast. The fact that there is a unique pathway of aromatase expression within the breast due to the promoter switching described previously allows in principle the possibility for this.
This leads to the concept of selective aromatase modulators or SAMs 
Role of LRH-1 in aromatase expression in the breast.
Aromatase expression from promoter II in the ovary requires the presence of activated CREB which binds to CRE in the promoter II sequence (51) . In the ovary CREB is activated via the signalling pathway which originates when FSH binds to its receptor and activates adenylyl cyclase. In addition to CREB binding to its CRE, activation of the promoter requires the presence of a monomeric orphan member of the nuclear receptor family to bind to a nuclear receptor half site downstream of the CRE. In the ovary this factor is steroidogenic factor 1 or SF1. In the case of adipose, no SF1 is present (52) so although PGE 2 can substitute for FSH in terms of the cyclic AMP signalling pathway, the question arises as to what factor occupies the nuclear receptor half site to activate promoter 2 in breast adipose. We tested a number of monomeric orphan nuclear receptors known to bind to such a half site including ERRα, Nurr1, Nor1, NGF1B and LRH-1 (52) . The only factor which could substitute for SF1 in terms of promoter II activation was LRH-1 or liver receptor homologue-1. SF1 and LRH-1 share a high degree of homology and both belong to the NR5A sub-family of nuclear receptors. In contrast to SF1, LRH-1 is expressed in human adipose tissue as well as in human breast tumors, whereas SF1 is not. Using Real Time PCR it was found that in adipose tissue, LRH-1 is expressed in the mesenchymal preadipocytes rather than in the adipocytes themselves, a similar distribution to that of aromatase.
Moreover upon differentiation of human preadipocytes to the lipid-laden phenotype, LRH-1 expression drops precipitiously preceding the loss of aromatase expression, suggesting that aromatase expression is dependent on LRH-1. LRH-1 and cyclic AMP activate promoter II synergistically in 3T3L1 preadipocytes and mutation of the nuclear receptor half-site completely abrogates this action of LRH-1 (52) .
Based on these studies therefore we can conclude that LRH-1 substitutes for SF1 in human breast preadipocytes to activate aromatase promoter II expression (Fig.6 ). Thus inhibition of LRH-1 would result in loss of aromatase activity in the breast and hence of estrogen biosynthesis. Therefore LRH-1 is a potential target for new breast-specific breast cancer therapies, since inhibitors of LRH-1 would specifically inhibit aromatase in breast and thus spare estrogen formation in other tissues. Thus they would serve as SAMS and thus could find utility as the next generation of breast cancer therapeutic agents.
Acknowledgements:
The work from this laboratory described in this review was supported by Table 1 Plasma steroid levels in postmenopausal women and in men 
